AYJK(SZ:002172) Zhong Zheng Wang·2025-11-07 08:28Core Insights - The company has achieved significant growth in profitability, with a net profit of 8.56 million yuan in Q3 2025, marking a substantial increase of 533.86% year-on-year, reaching a new high for the same period in recent years [1] - For the first three quarters of 2025, the cumulative net profit attributable to shareholders reached 40.11 million yuan, reflecting a year-on-year growth of 3.71%, demonstrating strong operational resilience despite short-term revenue adjustments [1] - The company’s core business profitability has improved, with a net profit of 2.35 million yuan in Q3 2025, up 63.23% year-on-year, indicating a substantial enhancement in core business performance [1] Profitability and Efficiency - The gross profit margin for the first three quarters of 2025 remained stable at 14.27%, while the net profit margin in Q3 increased to 1.91%, up 1.57 percentage points year-on-year, showcasing improved profitability quality during revenue structure adjustments [2] - The company has established a medical consortium centered around Aoyang Hospital, with over 2,300 total beds, covering comprehensive medical and rehabilitation services, thus forming a strong competitive advantage in the regional healthcare market [2] Shareholding Changes - The company’s shareholding change has been a focal point, with the controlling shareholder, Aoyang Group, transferring 20% of its shares to Zhangjiagang Yuesheng Technology Co., Ltd. for a total price of 593 million yuan, which has been completed [3] - Following the change in control, the new shareholder is expected to provide policy resource support, expand financing channels, and enhance regional business collaboration, thereby optimizing the company’s governance structure and strengthening its capital base for future development [3]